BRGSF-HIS mice as a predictive tool for safety assessment of biologics

BRGSF-HIS for safety assessment

September 13, 2024

Background

Immunotherapies are efficacious but are often associated to immune-related adverse events, such as cytokine release syndrome (CRS). Safety assessment of therapeutics in preclinical models remains challenging, as they should be relevant and translational. Models exhibiting a human immune system are widely used, but the composition of the human immune system developed remains a concern. Here we report the use of BRGSF mice, an immunodeficient mouse model which can be reconstituted with human cord blood CD34+ cells (BRGSF-CD34+) or PBMC (BRGSF-PBMC). BRGSF-CD34+ develop functional human lymphoid and myeloid compartments, with systematic and persistent presence of plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs), and monocytes/macrophages. Their myeloid and dendritic compartments can be transiently boosted with exogenous human Flt3L injections. In contrary to other models which overexpress human cytokines to develop human myeloid cells, Flt3L-treated BRGSF-CD34+ mice do not show side effects.

Related products

Catalogue product

genO‑BRGSF‑HIS

genO‑BRGSF‑HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Customized product

No items found.
Related posters
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe